NO20071619L - Fremgangsmate for fremstilling av indazol forbindelse - Google Patents
Fremgangsmate for fremstilling av indazol forbindelseInfo
- Publication number
- NO20071619L NO20071619L NO20071619A NO20071619A NO20071619L NO 20071619 L NO20071619 L NO 20071619L NO 20071619 A NO20071619 A NO 20071619A NO 20071619 A NO20071619 A NO 20071619A NO 20071619 L NO20071619 L NO 20071619L
- Authority
- NO
- Norway
- Prior art keywords
- preparation
- indazole compound
- formula
- indazole
- compounds
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- -1 indazole compound Chemical class 0.000 title 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000003453 indazolyl group Chemical class N1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62463504P | 2004-11-02 | 2004-11-02 | |
| US71707105P | 2005-09-14 | 2005-09-14 | |
| PCT/IB2005/003297 WO2006048744A1 (en) | 2004-11-02 | 2005-10-21 | Methods of preparing indazole compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20071619L true NO20071619L (no) | 2007-04-25 |
Family
ID=35744929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20071619A NO20071619L (no) | 2004-11-02 | 2007-03-28 | Fremgangsmate for fremstilling av indazol forbindelse |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7232910B2 (enExample) |
| EP (1) | EP1809621A1 (enExample) |
| JP (1) | JP2008518900A (enExample) |
| KR (1) | KR20070058690A (enExample) |
| AR (1) | AR051754A1 (enExample) |
| AU (1) | AU2005300310A1 (enExample) |
| BR (1) | BRPI0518203A2 (enExample) |
| CA (1) | CA2586174A1 (enExample) |
| IL (1) | IL182693A0 (enExample) |
| MX (1) | MX2007005291A (enExample) |
| NO (1) | NO20071619L (enExample) |
| RU (1) | RU2007116107A (enExample) |
| TW (1) | TWI294421B (enExample) |
| WO (1) | WO2006048744A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3252047B1 (en) * | 2007-04-05 | 2022-05-11 | Pfizer Products Inc. | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole suitable for the treatment of abnormal cell growth in mammals |
| JP5348725B2 (ja) | 2007-10-25 | 2013-11-20 | ジェネンテック， インコーポレイテッド | チエノピリミジン化合物の製造方法 |
| EP2163544A1 (en) * | 2008-09-16 | 2010-03-17 | Pfizer, Inc. | Methods of preparing indazole compounds |
| PT2373640E (pt) | 2009-01-08 | 2014-09-30 | Merck Patent Gmbh | Novas formas polimórficas do sal de cloridrato de 3-(1-{3- [5-(1-metil-piperidin-4-ilmetoxi)-pirimidin-2-il]-benzil}- 6-oxo-1,6-di-hidro-piridazin-3-il)-benzonitrilo e processos de fabrico das mesmas |
| WO2013046133A1 (en) | 2011-09-30 | 2013-04-04 | Pfizer Inc. | Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide |
| KR20140088556A (ko) | 2011-11-11 | 2014-07-10 | 화이자 인코포레이티드 | 만성 골수성 백혈병을 치료하기 위한 n-메틸-2-[3-((e)-2-피리딘-2-일-비닐)-1h-인다졸-6-일설파닐]-벤즈아미드 |
| US9899120B2 (en) | 2012-11-02 | 2018-02-20 | Nanotek Instruments, Inc. | Graphene oxide-coated graphitic foil and processes for producing same |
| US10087073B2 (en) | 2013-02-14 | 2018-10-02 | Nanotek Instruments, Inc. | Nano graphene platelet-reinforced composite heat sinks and process for producing same |
| EP2792360A1 (en) | 2013-04-18 | 2014-10-22 | IP Gesellschaft für Management mbH | (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV |
| WO2015067224A1 (en) | 2013-11-08 | 2015-05-14 | Zentiva, K.S. | Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole |
| PL3077397T3 (pl) * | 2013-12-06 | 2020-04-30 | Vertex Pharmaceuticals Inc. | Związek 2-amino-6-fluoro-n-[5-fluoro-pirydyn-3-ylo]pyrazolo [1,5-a]pirymidino-3-karboksamidu przydatny jako inhibitor kinazy atr, jego wytwarzanie, różne postacie stałe i ich radioznakowane pochodne |
| US10570202B2 (en) | 2014-02-04 | 2020-02-25 | Pfizer Inc. | Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer |
| EP3127900B1 (en) * | 2014-03-31 | 2017-10-18 | Senju Pharmaceutical Co., Ltd. | Alkynyl indazole derivative and use thereof |
| EP3185866A1 (en) | 2014-08-25 | 2017-07-05 | Pfizer Inc. | Combination of a pd-1 antagonist and an alk inhibitor for treating cancer |
| WO2016108106A1 (en) * | 2014-12-29 | 2016-07-07 | Shilpa Medicare Limited | An improved process for preparation of axitinib |
| CN112263677A (zh) | 2015-02-26 | 2021-01-26 | 默克专利股份公司 | 用于治疗癌症的pd-1/pd-l1抑制剂 |
| US9580406B2 (en) | 2015-04-28 | 2017-02-28 | Signa S.A. De C.V. | Processes for the preparation of axitinib |
| MX390878B (es) | 2015-06-16 | 2025-03-21 | Merck Patent Gmbh | Usos medicos de antagonista de ligando 1 de muerte programada (pd-l1). |
| BR112019006504A2 (pt) | 2016-10-06 | 2019-06-25 | Pfizer Inc. | regime de dosagem de avelumabe para o tratamento de câncer |
| US20220370606A1 (en) | 2018-12-21 | 2022-11-24 | Pfizer Inc. | Combination Treatments Of Cancer Comprising A TLR Agonist |
| EA202192731A1 (ru) | 2019-04-18 | 2022-02-04 | Синтон Б.В. | СПОСОБ ПОЛУЧЕНИЯ АКСИТИНИБА, СПОСОБ ОЧИСТКИ ПРОМЕЖУТОЧНОГО СОЕДИНЕНИЯ 2-((3-ЙОД-1H-ИНДАЗОЛ-6-ИЛ)ТИО)-N-МЕТИЛБЕНЗАМИДА, СПОСОБ ОЧИСТКИ АКСИТИНИБА ЧЕРЕЗ HCl СОЛЬ АКСИТИНИБА, ТВЕРДАЯ ФОРМА HCl СОЛИ АКСИТИНИБА |
| US20240117030A1 (en) | 2022-03-03 | 2024-04-11 | Pfizer Inc. | Multispecific antibodies and uses thereof |
| WO2025157389A1 (en) | 2024-01-22 | 2025-07-31 | Iomx Therapeutics Ag | Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI262914B (en) * | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| EP1606283B1 (en) * | 2003-03-03 | 2008-10-08 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| EP1613320A1 (en) * | 2003-04-03 | 2006-01-11 | Pfizer Inc. | Dosage forms comprising ag013736 |
| US20080274192A1 (en) | 2005-05-19 | 2008-11-06 | Pfizer Inc. | Pharmaceutical Compositions Comprising an Amorphous Form of a Vegf-R-Inhibitor |
-
2005
- 2005-10-21 BR BRPI0518203-4A patent/BRPI0518203A2/pt not_active IP Right Cessation
- 2005-10-21 EP EP05804650A patent/EP1809621A1/en not_active Withdrawn
- 2005-10-21 KR KR1020077009848A patent/KR20070058690A/ko not_active Ceased
- 2005-10-21 WO PCT/IB2005/003297 patent/WO2006048744A1/en not_active Ceased
- 2005-10-21 RU RU2007116107/04A patent/RU2007116107A/ru not_active Application Discontinuation
- 2005-10-21 AU AU2005300310A patent/AU2005300310A1/en not_active Abandoned
- 2005-10-21 JP JP2007538537A patent/JP2008518900A/ja not_active Withdrawn
- 2005-10-21 MX MX2007005291A patent/MX2007005291A/es not_active Application Discontinuation
- 2005-10-21 CA CA002586174A patent/CA2586174A1/en not_active Abandoned
- 2005-10-28 TW TW094137922A patent/TWI294421B/zh active
- 2005-10-31 US US11/264,440 patent/US7232910B2/en not_active Expired - Fee Related
- 2005-11-01 AR ARP050104568A patent/AR051754A1/es unknown
-
2007
- 2007-03-28 NO NO20071619A patent/NO20071619L/no not_active Application Discontinuation
- 2007-04-19 IL IL182693A patent/IL182693A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20060094881A1 (en) | 2006-05-04 |
| KR20070058690A (ko) | 2007-06-08 |
| BRPI0518203A2 (pt) | 2009-03-10 |
| JP2008518900A (ja) | 2008-06-05 |
| TWI294421B (en) | 2008-03-11 |
| TW200621721A (en) | 2006-07-01 |
| CA2586174A1 (en) | 2006-05-11 |
| WO2006048744A1 (en) | 2006-05-11 |
| US7232910B2 (en) | 2007-06-19 |
| RU2007116107A (ru) | 2008-11-10 |
| IL182693A0 (en) | 2007-09-20 |
| AR051754A1 (es) | 2007-02-07 |
| AU2005300310A1 (en) | 2006-05-11 |
| EP1809621A1 (en) | 2007-07-25 |
| MX2007005291A (es) | 2007-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20071619L (no) | Fremgangsmate for fremstilling av indazol forbindelse | |
| NO20071242L (no) | Triazolpyridinylsulfanylderivater som P38-MAP-kinaseinhibitorer | |
| NO20083918L (no) | Dihydridiazepiner anvendelige som inhibitorer av proteinkinaser | |
| NO20073140L (no) | Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser | |
| NO20083220L (no) | Heterocykliske derivater som modulatorer for ionekanaler | |
| NO20084747L (no) | Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser | |
| NO20072567L (no) | Triazoler nyttige som proteinkinase-inhibitorer | |
| NO20082482L (no) | Karbonylamino pyrrolpyrazoler, samt anvendelse som kinase inhibitorer | |
| NO20064976L (no) | Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser | |
| NO20065727L (no) | Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter | |
| WO2007079164A3 (en) | Protein kinase inhibitors | |
| NO20072963L (no) | 5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere | |
| EA201000149A1 (ru) | Производные 1-фенил-2-пиридинилалкиловых спиртов в качестве ингибиторов фосфодиэстераз | |
| NO20090628L (no) | Pyridizinon derivativater | |
| NO20084652L (no) | Deazapuriner anvendelige som inhibitorer av januskinaser | |
| NO20051100L (no) | Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer | |
| NO20073628L (no) | Pyridoner som er nyttige som inhibitorer av kinaser | |
| NO20066055L (no) | Pyridinderivater | |
| WO2008131000A3 (en) | 7-substituted indole mcl-1 inhibitors | |
| ATE362932T1 (de) | Azaindolverbindungen als kinaseinhibitoren | |
| NO20073859L (no) | Pyrrolopyrazoler, potente kinaseinhibitorer | |
| NO20081454L (no) | Met-kinaseinhibitorer | |
| WO2008061108A3 (en) | Phthalazine derivatives | |
| WO2008005877A3 (en) | Inhibitors of c-kit and uses thereof | |
| NO20083501L (no) | Azaindoler som er anvendelige som inhibitorer for Janus-kinaser |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |